| Original language | English (US) |
|---|---|
| Pages (from-to) | 219-220 |
| Number of pages | 2 |
| Journal | Neuropsychopharmacology |
| Volume | 44 |
| Issue number | 1 |
| DOIs | |
| State | Published - Jan 1 2019 |
Bibliographical note
Funding Information:A.S.W. acknowledges support from the OneMind Institute, National Institutes of Health (contracts MH10972, MH111320, NS100548, and MH113103), MnDRIVE Brain Conditions initiative, and MnDRIVE Medical Discovery Team on Addictions. A.B.H. acknowledges support from the MnDRIVE Brain Conditions initiative.Competing interests: The authors declare no competing interests.
Funding Information:
Recherche Médicale "Equipe FRM DEQ2014039529", the French Ministry of Research (Agence Nationale pour la Recherche ANR-17-CE16-0008 and the Investissements d'Avenir programme ANR-11-IDEX-0004-02) and the DIM Cerveau et Pensé région Ile-de-France (PME2012). L.M.'s team is part of the École des Neurosciences de Paris Ile-de-France network and of the Bio-Psy Labex and as such this work was supported by French state funds managed by the ANR within the Investissements d'Avenir programme under reference ANR-11-IDEX-0004-02.Competing interests: The authors declare no competing interests.